Guideline No. 398: Progesterone for Prevention of Spontaneous Preterm Birth.

Guideline No. 398: Progesterone for Prevention of Spontaneous Preterm Birth. J Obstet Gynaecol Can. 2020 Jun;42(6):806-812 Authors: Jain V, McDonald SD, Mundle WR, Farine D Abstract OBJECTIVES: To assess the benefits and risks of progesterone therapy for women at increased risk of spontaneous preterm birth (SPB) and to make recommendations for the use of progesterone to reduce the risk of SPB and improve postnatal outcomes. OPTIONS: To administer or withhold progesterone therapy for women deemed to be at high risk of SPB. OUTCOMES: Preterm birth, neonatal morbidity and mortality, and postnatal outcomes including neurodevelopmental outcomes. INTENDED USERS: Maternity care providers, including midwives, family physicians, and obstetricians. TARGET POPULATION: Pregnant women at increased risk of SPB. EVIDENCE: Medline, PubMed, EMBASE, and the Cochrane Library were searched from inception to October 2018 for medical subject heading (MeSH) terms and keywords related to pregnancy, preterm birth, previous preterm birth, short cervix, uterine anomalies, cervical conization, neonatal morbidity and mortality, and postnatal outcomes. This document represents an abstraction of the evidence rather than a methodological review. VALIDATION METHODS: This guideline was reviewed by the Maternal-Fetal Medicine Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC) and approved by th...
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research